Overview Dividends

(ABT) Abbott Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000

Pharmaceuticals, Diagnostics, Nutrition, Devices

Health Care Equipment
Market Cap in USD: 217,766m

IPO / Inception: 1978-01-13
Return 12m vs S&P 500: -3.42%

EPS (Earnings per Share)

EPS CAGR: -0.41%
EPS Trend: -32.7%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: -0.23%
Rev. Trend: -8.5%

Last SUE: -0.19
Qual. Beats: 0

Dividends

Dividend Yield	1.88%
Yield on Cost 5y	2.39%
Yield CAGR 5y	11.18%
Payout Consistency	92.6%
Payout Ratio	51.5%

Risk via 5d forecast
Volatility	19.8%
Value at Risk 5%th	30.4%
Relative Tail Risk	-6.76%

Reward TTM
Sharpe Ratio	0.52
Alpha	6.16
CAGR/Max DD	0.34

Character TTM
Hurst Exponent	0.293
Beta	0.244
Beta Downside	0.438

Drawdowns 3y
Max DD	20.88%
Mean DD	6.80%
Median DD	5.89%

Description: ABT Abbott Laboratories December 01, 2025

Abbott Laboratories (NYSE: ABT) is a diversified health-care company that operates across four core segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The firm markets a broad portfolio ranging from generic drugs for gastrointestinal, metabolic, and cardiovascular conditions to point-of-care diagnostic platforms, infant nutrition, and cardiovascular-plus-neuromodulation devices.

In fiscal 2023 Abbott reported revenue of approximately $43 billion, an operating margin of about 28 %, and earnings per share of $2.85, supported by a 7 % year-over-year increase in diagnostics sales driven largely by molecular testing and rapid-test platforms. The company’s R&D spend was $2.5 billion (≈5.8 % of revenue), reflecting continued investment in next-generation device and assay technologies.

Key drivers of Abbott’s outlook include the aging U.S. and global populations, which raise demand for chronic-disease therapeutics and home-based monitoring; sustained growth in health-care spending (≈5 % CAGR worldwide); and the industry-wide shift toward outpatient and point-of-care services, which benefits Abbott’s diagnostic and device segments. A potential risk is heightened regulatory scrutiny on generic pricing and device approvals, which could compress margins if not managed.

For a deeper quantitative assessment, you might explore ValueRay’s detailed valuation models for ABT.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.63b TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA -0.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 23.39% (prev 21.59%; Δ 1.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 9.12b <= Net Income 13.98b (YES >=105%, WARN >=100%)

Net Debt (5.43b) to EBITDA (11.72b) ratio: 0.46 <= 3.0 (WARN <= 3.5)

Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.06% (target <= -2.0% for YES)

Gross Margin 53.98% (prev 50.98%; Δ 3.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.31% (prev 55.43%; Δ -0.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 19.04 (EBITDA TTM 11.72b / Interest Expense TTM 451.0m) >= 6 (WARN >= 3)

Altman Z'' 5.59

(A) 0.12 = (Total Current Assets 24.84b - Total Current Liabilities 14.58b) / Total Assets 84.18b

(B) 0.58 = Retained Earnings (Balance) 49.10b / Total Assets 84.18b

(D) 2.06 = Book Value of Equity 67.83b / Total Liabilities 32.92b

Total Rating: 5.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.07

1. Piotroski 5.0pt

2. FCF Yield 3.10%

3. FCF Margin 15.78%

4. Debt/Equity 0.25

5. Debt/Ebitda 0.46

6. ROIC - WACC (= 3.76)%

7. RoE 28.24%

8. Rev. Trend -8.51%

9. EPS Trend -32.69%

What is the price of ABT shares?

As of December 22, 2025, the stock is trading at USD 125.45 with a total of 13,086,982 shares traded.
Over the past week, the price has changed by -2.35%, over one month by -2.08%, over three months by -7.77% and over the past year by +11.82%.

Is ABT a buy, sell or hold?

Abbott Laboratories has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy ABT.

Strong Buy: 12
Buy: 7
Hold: 9
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ABT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	144.4	15.1%
Analysts Target Price	144.4	15.1%
ValueRay Target Price	123.6	-1.5%

ABT Fundamental Data Overview December 20, 2025

Market Cap USD = 217.77b (217.77b USD * 1.0 USD.USD)
P/E Trailing = 15.7186
P/E Forward = 22.3214
P/S = 4.967
P/B = 4.3241
P/EG = 4.1675
Beta = 0.714
Revenue TTM = 43.84b USD
EBIT TTM = 8.59b USD
EBITDA TTM = 11.72b USD
Long Term Debt = 11.60b USD (from longTermDebt, last quarter)
Short Term Debt = 1.34b USD (from shortTermDebt, last quarter)
Debt = 12.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.43b USD (from netDebt column, last quarter)
Enterprise Value = 223.20b USD (217.77b + Debt 12.94b - CCE 7.51b)
Interest Coverage Ratio = 19.04 (Ebit TTM 8.59b / Interest Expense TTM 451.0m)
FCF Yield = 3.10% (FCF TTM 6.92b / Enterprise Value 223.20b)
FCF Margin = 15.78% (FCF TTM 6.92b / Revenue TTM 43.84b)
Net Margin = 31.88% (Net Income TTM 13.98b / Revenue TTM 43.84b)
Gross Margin = 53.98% ((Revenue TTM 43.84b - Cost of Revenue TTM 20.18b) / Revenue TTM)
Gross Margin QoQ = 55.75% (prev 56.44%)
Tobins Q-Ratio = 2.65 (Enterprise Value 223.20b / Total Assets 84.18b)
Interest Expense / Debt = 0.34% (Interest Expense 44.0m / Debt 12.94b)
Taxrate = 24.59% (536.0m / 2.18b)
NOPAT = 6.48b (EBIT 8.59b * (1 - 24.59%))
Current Ratio = 1.70 (Total Current Assets 24.84b / Total Current Liabilities 14.58b)
Debt / Equity = 0.25 (Debt 12.94b / totalStockholderEquity, last quarter 50.95b)
Debt / EBITDA = 0.46 (Net Debt 5.43b / EBITDA 11.72b)
Debt / FCF = 0.79 (Net Debt 5.43b / FCF TTM 6.92b)
Total Stockholder Equity = 49.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.60% (Net Income 13.98b / Total Assets 84.18b)
RoE = 28.24% (Net Income TTM 13.98b / Total Stockholder Equity 49.50b)
RoCE = 14.06% (EBIT 8.59b / Capital Employed (Equity 49.50b + L.T.Debt 11.60b))
RoIC = 10.29% (NOPAT 6.48b / Invested Capital 62.93b)
WACC = 6.54% (E(217.77b)/V(230.71b) * Re(6.91%) + D(12.94b)/V(230.71b) * Rd(0.34%) * (1-Tc(0.25)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.03%
[DCF Debug] Terminal Value 77.94% ; FCFE base≈6.74b ; Y1≈6.59b ; Y5≈6.67b
Fair Price DCF = 68.12 (DCF Value 118.45b / Shares Outstanding 1.74b; 5y FCF grow -3.37% → 3.0% )
EPS Correlation: -32.69 | EPS CAGR: -0.41% | SUE: 0.0 | # QB: 0
Revenue Correlation: -8.51 | Revenue CAGR: -0.23% | SUE: -0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.20 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=20
EPS next Year (2026-12-31): EPS=5.68 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+10.2% | Growth Revenue=+7.9%

Additional Sources for ABT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle